The pharmaceutical firm issued a statement saying, “We are committed to continuously monitoring, evaluating, and reporting safety information for all Lilly medicines.”
“Mounjaro (tirzepatide) was authorized after a thorough evaluation of the medication’s risks and advantages.
To make sure prescribers have access to the most recent information, we also provide regulators worldwide information on the risks and benefits of all of our medications.
Anyone should speak with their doctor or another healthcare provider if they are having adverse affects from taking any Lilly medications.
